From this article presented as in-progress update on the PSMAddition trial, from ESMO 2021:
…the statement is made that:
“…androgen receptor pathway inhibitors (ARPI) have been utilized in this disease space and metastatic hormone-sensitive prostate cancer (mHSPC) for many years. Notably, ARPI treatment may alter PSMA expression and radiosensitivity. ”
I have two questions:
1– am I correct that ARPI includes ENZ and ABI?
2– do we know what is the hypothesis here, i.e. when we say “alter PSMA expression and radiosensitity”, does this mean favorably or unfavorably?
Thanks for your thoughts.